Who
Marco Taglietti
Director
Company insider
Files Form 4 as: Director, Aquestive Therapeutics; Chief Executive Officer, Scynexis; Director, Delcath Systems; Director, NephroGenex; EVP-Drug Dev & Ch.Medical Off., Forest Laboratories.
In numbers
- Trades disclosed
- 133
- Buys
- 33
- Sells
- 3
- Bought
- $2.2M
- Sold
- $664K
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 13 Aug 2007
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —50,500 at $0.00 | filing |
| 11 Jun 2025filed 12 Jun 2025 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | $143K42,000 at $3.41 | filing |
| 20 Jun 2024filed 21 Jun 2024 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —38,000 at $0.00 | filing |
| 21 Jun 2023filed 23 Jun 2023 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 22 Jun 2022filed 24 Jun 2022 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 26 Apr 2022filed 28 Apr 2022 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 | filing |
| 26 Apr 2022filed 28 Apr 2022 | SCYX ScynexisBiotechnology | SEC FORM 4 Bought | $225K75,000 at $3.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —232,000 at $0.00 | filing |
| 4 Feb 2022filed 8 Feb 2022 | SCYX ScynexisBiotechnology | SEC FORM 4 Code A | —87,200 at $0.00 | filing |
| 15 Jun 2021filed 17 Jun 2021 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 11 Mar 2021filed 15 Mar 2021 | AQST Aquestive Therapeuticsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —28,500 at $0.00 | filing |
| 29 Jan 2021filed 2 Feb 2021 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —170,000 at $0.00 | filing |
| 21 Dec 2020filed 23 Dec 2020 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 | filing |
| 21 Dec 2020filed 23 Dec 2020 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 | filing |
| 21 Dec 2020filed 23 Dec 2020 | SCYX ScynexisBiotechnology | SEC FORM 4 Bought | $250K40,000 at $6.25 | filing |
| 8 May 2020filed 8 May 2020 | DCTH Delcath Systemsoption or derivative · Medical Devices | SEC FORM 4 Code C | —60 at $0.00 | filing |
| 8 May 2020filed 8 May 2020 | DCTH Delcath SystemsMedical Devices | SEC FORM 4 Code C | —6,000 | filing |
| 31 Jan 2020filed 4 Feb 2020 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code A | —900,000 at $0.00 | filing |
| 12 Dec 2019filed 16 Dec 2019 | SCYX Scynexisoption or derivative · Biotechnology | SEC FORM 4 Code P | —166,667 | filing |
News
Head-To-Head Analysis: Delcath Systems (NASDAQ:DCTH) & Neogen (NASDAQ:NEOG)DCTH · themarketsdaily.com · 18 Oct 2026Analyzing Green Thumb Industries (OTCMKTS:GTBIF) and Delcath Systems (NASDAQ:DCTH)DCTH · dailypolitical.com · 10 Oct 2026Head to Head Review: Delcath Systems (NASDAQ:DCTH) and Green Thumb Industries (OTCMKTS:GTBIF)DCTH · themarketsdaily.com · 8 Oct 2026SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYX · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Marco Taglietti; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.